Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions The Cardiovascular, Oncology And Central Nervous System (CNS) Therapeutics Account For More Than 50% Of The Total Sales Cardiovascular, oncology and CNS therapeutics accounted for more than 50% of the total pharmaceutical market by indication. The three therapeutic segments accounted for 52% of the total pharmaceutical market. Cardiovascular disorder therapeutics accounted for 19% of the total market share, closely followed by oncology therapeutics with 18% and CNS therapeutics with 15% of the total pharmaceutical market share. These three major indications contribute the most to the total pharmaceutical market. The high market share of cardiovascular, oncology and CNS therapeutics indicates that these therapeutic areas will decide the way forward for the global pharmaceutical industry. Majority of the pharmaceutical companies deal in these three therapeutic areas and their endeavour has been to increase and consolidate their portfolio in these therapeutic areas. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Pharmaceutical-Industry-2010-YearbookTherapeutic-Market-Landscape-Key-Pipeline-DrugsTop-Pharma-Companies-and-KeyMergers-andAcquisitions&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare Strategic consolidations by major pharmaceutical companies are changing the global pharmaceutical market scenario. The major mergers and acquisitions (M&A) deals of 2009 were acquisition of Wyeth by Pfizer, Genentech by Roche and the merger of Merck and Schering-Plough. The dynamic nature of the pharmaceutical industry is expected to continue because patent expirations of major blockbuster drugs will lead the pharmaceutical companies to consider strategic consolidations to maintain their market position and, to have pipeline drugs. Pharmaceutical companies need to find alternative options to maintain their revenue generation and this can be done by acquiring regional and niche players. It is important for pharmaceutical companies to plan for the long term, so that the slow pace of research and development (R&D) can be objectively managed. The acquisition of small and niche pharmaceutical companies by major pharmaceutical companies show a very dynamic future scenario in the pharmaceutical arena. The contribution in M&A deals involving oncology to the total value of M&A deals was 35%. This signifies that the oncology therapeutics area witnessed M&A deals of the highest value. This was followed by cardiovascular and CNS therapeutics contributing 20% and 19% respectively to the total value of M&A deals. More than 70% of the total value of M&A deals was from oncology, cardiovascular and CNS therapeutics. This indicates the high value of M&A deals in oncology, cardiovascular and CNS therapeutics.
For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Pharmaceutical-Industry-2010-YearbookTherapeutic-Market-Landscape-Key-Pipeline-DrugsTop-Pharma-Companies-and-KeyMergers-andAcquisitions&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@gbiresearch.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782